Skip to Content

Cerdelga (eliglustat) Disease Interactions

There are 3 disease interactions with Cerdelga (eliglustat):


Eliglustat (Includes Cerdelga) ↔ Liver Impairment

Severe Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Eliglustat has not been studied in patients with hepatic impairment. Its use is not recommended in patients with any stage of hepatic impairment or cirrhosis.


Eligustat (Includes Cerdelga) ↔ Preexisting Heart Conditions

Severe Potential Hazard, Moderate plausibility

Applies to: Heart Disease

The use of eliglustat is contraindicated in patients who are CYP2D6 extensive metabolizers or intermediate metabolizers taking a strong or moderate CYP2D6 inhibitor concomitantly with a strong or moderate CYP3A inhibitor or those who are intermediate metabolizers or poor metabolizers taking a strong CYP3A inhibitor due to the risk of a significant increase in drug plasma concentrations. Eliglustat is predicted to cause increases in EKG intervals (PR, QTc, and QRS) at high plasma concentrations and could result in arrhythmias; therefore, its use is not recommended in patients with preexisting cardiac disease (congestive heart failure, recent myocardial infarction, heart block, arrhythmias), or long QT syndrome.


Eliglustat (Includes Cerdelga) ↔ Renal Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Eliglustat has not been studied in patients with moderate to severe renal impairment or end-stage renal disease and its use is not recommended in these patients. No dosage adjustment is required for patients with mild renal impairment.

Cerdelga (eliglustat) drug Interactions

There are 508 drug interactions with Cerdelga (eliglustat)

Cerdelga (eliglustat) alcohol/food Interactions

There is 1 alcohol/food interaction with Cerdelga (eliglustat)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.